In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
21 authors.
Shunya NakayamaDepartment of Hematology and Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.ORCID 0000-0001-9664-609X Akane KanamoriDepartment of Molecular Life Sciences, Tokai University School of Medicine, Isehara, Kanagawa, Japan.ORCID 0009-0005-6171-9363 Takeshi KamakuraDepartment of Regulation of Infectious Cancer, Division of Cellular and Molecular Biology, Research Institute for Microbial Diseases, The University of Osaka, Suita, Osaka, Japan.ORCID 0009-0002-4523-8971 Kosuke KamiyaDepartment of Innovative Medical Science, Tokai University School of Medicine, Isehara, Kanagawa, Japan.ORCID 0009-0002-8437-6146 Kai KudoDepartment of Innovative Medical Science, Tokai University School of Medicine, Isehara, Kanagawa, Japan.ORCID 0000-0002-5410-3334 Ryo YanagiyaDepartment of Hematology and Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.ORCID 0000-0002-2092-8194 Takanobu ShimizuDepartment of Innovative Medical Science, Tokai University School of Medicine, Isehara, Kanagawa, Japan.ORCID 0000-0003-1186-0703 Yoshimi MikiLaboratory of Microenvironmental Metabolic Health Sciences, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-8587-0333 Yuki NagasakiLaboratory of Microenvironmental Metabolic Health Sciences, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-4717-6877 Masaya ArakiDepartment of Endocrinology and Metabolism, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.ORCID 0009-0004-4376-4278 Koichiro TateishiDepartment of Virology, Division of Host Defense Mechanism, Tokai University School of Medicine, Isehara, Kanagawa, Japan.ORCID 0000-0001-5964-4140 Yoko ItoDivision of Pulmonary Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan.ORCID 0000-0002-7791-1967 Yoshiki ShiraishiDivision of Pulmonary Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan.ORCID 0000-0001-5275-6318 Yasushi NakamotoDepartment of Innovative Medical Science, Tokai University School of Medicine, Isehara, Kanagawa, Japan.ORCID 0009-0008-6546-2448 Hiroyuki HosokawaDepartment of Immunology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.ORCID 0000-0002-9592-2889 Yumi MatsuzakiDepartment of Life Science, Shimane University Faculty of Medicine, Izumo, Shimane, Japan.ORCID 0000-0002-3729-2997 Hitoshi ShimanoDepartment of Endocrinology and Metabolism, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.ORCID 0000-0002-5562-5572 Koichiro AsanoDivision of Pulmonary Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan.ORCID 0000-0002-9044-3061 Norio YamamotoDepartment of Virology, Division of Host Defense Mechanism, Tokai University School of Medicine, Isehara, Kanagawa, Japan.ORCID 0000-0002-5574-1960 Makoto MurakamiLaboratory of Microenvironmental Metabolic Health Sciences, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-4565-6017 Ai KotaniDepartment of Regulation of Infectious Cancer, Division of Cellular and Molecular Biology, Research Institute for Microbial Diseases, The University of Osaka, Suita, Osaka, Japan.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Because cytokine storm syndromes such as sepsis, acute respiratory distress syndrome (ARDS), and coagulopathy, including those seen in COVID-19, are fatal, development of highly effective therapeutics is urgently needed. Recent evidence suggests that the hydrolysis of phospholipids in extracellular vesicles (EVs) by secreted phospholipase A
Indexed as
Cytokine Release SyndromeExtracellular VesiclesPhospholipases A2, SecretoryAnimalsCOVID-19HumansMembrane FluidityPhospholipidsSARS-CoV-2Phospholipases A2, SecretoryPhospholipids
Identifiers
PMID42536729
PMCPMC13426417
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390